{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:54:36Z","timestamp":1790960076805,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Schizophrenia is increasingly conceptualized as a disorder of chronic, unresolved neuroinflammation, yet why the inflammatory burden fails to resolve remains unclear. Specialized pro-resolving lipid mediators\u2014including resolvin D1 (RvD1) and lipoxin A4 (LXA4)\u2014actively terminate inflammation but have rarely been examined in schizophrenia. Because no previous study has measured LXA4 in schizophrenia or assessed both mediators concurrently, we compared serum RvD1 and LXA4 levels between patients and controls and assessed their association with illness severity. In this single-center case-control study, fasting serum RvD1 and LXA4 were measured by ELISA in 35 patients with schizophrenia (DSM-5) during an acute psychotic episode and 35 healthy controls of comparable age and sex; severity was rated with the PANSS and the Clinical Global Impression\u2013Severity (CGI-S) scale. Both mediators were significantly lower in patients than controls (RvD1: 3372 \u00b1 863 vs 3981 \u00b1 382 ng\/L, p &amp;lt; 0.001, Cohen\u2019s d = \u22120.91; LXA4: p = 0.002), and each remained independently associated with case status after adjustment for age, sex, and body mass index. Lower RvD1 correlated with higher CGI-S scores (\u03c1 = \u22120.54, p = 0.001), whereas LXA4 did not. This provides preliminary evidence that circulating levels of these pro-resolving lipid mediators are reduced in schizophrenia, consistent with altered pro-resolving signalling rather than a demonstrated failure of the resolution process itself. Overall, they identify RvD1 as a candidate severity-related biomarker in patients during an acute psychotic episode, warranting confirmation in larger, longitudinal, mass spectrometry-based studies.<\/jats:p>","DOI":"10.3389\/fpsyt.2026.1943920","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:34:00Z","timestamp":1790958840000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced serum levels of the pro-resolving lipid mediators resolvin D1 and lipoxin A4 in schizophrenia"],"prefix":"10.3389","volume":"17","author":[{"given":"Muhammet","family":"Sancaktar","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahadir","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulcin","family":"Elboga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feridun","family":"Bulbul","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Ercan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyithan","family":"Taysi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Alt\u0131ndag","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Faculty of Medicine, Gaziantep University","place":["Gaziantep, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","volume-title":"Kaplan and Sadock's Pocket Handbook of Clinical Psychiatry","author":"Sadock","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3389\/fnins.2015.00372","article-title":"The role of inflammation in schizophrenia","volume":"9","author":"M\u00fcller","year":"2015","journal-title":"Front Neurosci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0306-9877(95)90062-4","article-title":"The macrophage-T-lymphocyte theory of schizophrenia: additional evidence","volume":"45","author":"Smith","year":"1995","journal-title":"Med Hypotheses"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158477","article-title":"The interrelationships between cytokines and schizophrenia: a systematic review","volume":"25","author":"Lv","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Pro-resolving lipid mediators are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27154836","article-title":"Specialized pro-resolving mediators in neuroinflammation: overview of studies and perspectives of clinical applications","volume":"27","author":"Valente","year":"2022","journal-title":"Molecules"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.780811","article-title":"Role of specialized pro-resolving mediators in reducing neuroinflammation in neurodegenerative disorders","volume":"14","author":"Ponce","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.01.003","article-title":"Biased activation of inflammation pro-resolving receptors as an evolving supportive strategy in schizophrenia treatment","volume":"228","author":"Kalinkovich","year":"2021","journal-title":"Schizophr Res."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2015.05.013","article-title":"The role of polyunsaturated fatty acids and GPR40 receptor in brain","volume":"113","author":"Khan","year":"2017","journal-title":"Neuropharmacology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.08.014","article-title":"A meta-analysis of the polyunsaturated fatty acid composition of erythrocyte membranes in schizophrenia","volume":"141","author":"Van der Kemp","year":"2012","journal-title":"Schizophr Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.1663","article-title":"Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages","volume":"164","author":"Godson","year":"2000","journal-title":"J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1021\/bi00044a041","article-title":"Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils","volume":"34","author":"Serhan","year":"1995","journal-title":"Biochemistry"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m300218200","article-title":"Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells: autacoids in anti-inflammation","volume":"278","author":"Hong","year":"2003","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14962","article-title":"Resolvin D1 ameliorates cognitive impairment following traumatic brain injury via protecting astrocytic mitochondria","volume":"154","author":"Ren","year":"2020","journal-title":"J Neurochem"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1891","article-title":"Resolvin D1: A key endogenous inhibitor of neuroinflammation","volume":"48","author":"Roohbakhsh","year":"2022","journal-title":"Biofactors"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.09060802","article-title":"International consensus study of antipsychotic dosing","volume":"167","author":"Gardner","year":"2010","journal-title":"Am J Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2019.1673480","article-title":"Resolvin D1 as a novel anti-inflammatory marker in manic, depressive and euthymic states of bipolar disorder","volume":"74","author":"Kok Kendirlioglu","year":"2020","journal-title":"Nordic J Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0055859","article-title":"Proresolution lipid mediators in multiple sclerosis\u2014differential, disease severity-dependent synthesis\u2014a clinical pilot trial","volume":"8","author":"Pr\u00fcss","year":"2013","journal-title":"PloS One"},{"key":"B23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s12888-024-05724-0","article-title":"The relationship between serum resolvin D1, NLRP3, cytokine levels, and adolescents with first-episode medication-na\u00efve major depressive disorder","volume":"24","author":"Guo","year":"2024","journal-title":"BMC Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-018-0889-z","article-title":"Resolvin D1 halts remote neuroinflammation and improves functional recovery after focal brain damage via ALX\/FPR2 receptor-regulated microRNAs","volume":"55","author":"Bisicchia","year":"2018","journal-title":"Mol Neurobiol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jalz.2013.12.024","article-title":"Resolution of inflammation is altered in Alzheimer's disease","volume":"11","author":"Wang","year":"2015","journal-title":"Alzheimer's Dementia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s0920-9964(97)00151-5","article-title":"The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia","volume":"30","author":"Horrobin","year":"1998","journal-title":"Schizophr Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2023.1163764","article-title":"Correlations between omega-3 fatty acids and inflammatory\/glial abnormalities: the involvement of the membrane and neurotransmitter dysfunction in schizophrenia","volume":"17","author":"Zhang","year":"2023","journal-title":"Front Cell Neurosci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.182","article-title":"Polyunsaturated fatty acid deficiency during neurodevelopment in mice models the prodromal state of schizophrenia through epigenetic changes in nuclear receptor genes","volume":"7","author":"Maekawa","year":"2017","journal-title":"Transl Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jpsychires.2015.11.013","article-title":"A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia","volume":"73","author":"Pawe\u0142czyk","year":"2016","journal-title":"J Psychiatr Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0269881120981392","article-title":"Effects of omega-3 polyunsaturated fatty acids supplements on psychopathology and metabolic parameters in schizophrenia: A meta-analysis of randomized controlled trials","volume":"35","author":"Goh","year":"2021","journal-title":"J Psychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2009.192","article-title":"Long-chain \u03c9-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial","volume":"67","author":"Amminger","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2021.09.018","article-title":"The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial","volume":"99","author":"Susai","year":"2022","journal-title":"Brain Behavior Immun"},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1016\/S2215-0366(21)00286-8","article-title":"Associations between plasma fatty acid concentrations and schizophrenia: a two-sample Mendelian randomisation study","volume-title":"Lancet Psychiatry.","author":"Jones","year":"2021"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01160-8","article-title":"Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis","volume":"26","author":"Borsini","year":"2021","journal-title":"Mol Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838782","article-title":"Formation, signaling and occurrence of specialized pro-resolving lipid mediators\u2014what is the evidence so far","volume":"13","author":"Schebb","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1943920\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:34:02Z","timestamp":1790958842000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1943920\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":35,"alternative-id":["10.3389\/fpsyt.2026.1943920"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1943920","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1943920"}}